JP2020523029A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523029A5 JP2020523029A5 JP2019569397A JP2019569397A JP2020523029A5 JP 2020523029 A5 JP2020523029 A5 JP 2020523029A5 JP 2019569397 A JP2019569397 A JP 2019569397A JP 2019569397 A JP2019569397 A JP 2019569397A JP 2020523029 A5 JP2020523029 A5 JP 2020523029A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- cancer
- hue71
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762520382P | 2017-06-15 | 2017-06-15 | |
| US62/520,382 | 2017-06-15 | ||
| PCT/US2018/037645 WO2018232188A1 (en) | 2017-06-15 | 2018-06-14 | Anti-l1-cam antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523029A JP2020523029A (ja) | 2020-08-06 |
| JP2020523029A5 true JP2020523029A5 (enExample) | 2021-07-26 |
| JP7353187B2 JP7353187B2 (ja) | 2023-10-05 |
Family
ID=64660699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569397A Active JP7353187B2 (ja) | 2017-06-15 | 2018-06-14 | 抗ｌ１－ｃａｍ抗体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11597764B2 (enExample) |
| EP (1) | EP3638299A4 (enExample) |
| JP (1) | JP7353187B2 (enExample) |
| CN (2) | CN111093693B (enExample) |
| CA (1) | CA3067351A1 (enExample) |
| IL (1) | IL271398A (enExample) |
| WO (1) | WO2018232188A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150131208A (ko) | 2013-03-13 | 2015-11-24 | 이미지냅 인코포레이티드 | Cd８에의 항원 결합 구조체들 |
| CN108136012B (zh) | 2015-08-07 | 2022-10-04 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
| CA3067351A1 (en) * | 2017-06-15 | 2018-12-20 | Nai-Kong Cheung | Anti-l1-cam antibodies and uses thereof |
| MX2020013923A (es) | 2018-06-29 | 2021-03-29 | Apitbio Inc | Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos. |
| CA3133074A1 (en) * | 2019-03-11 | 2020-09-17 | Memorial Sloan Kettering Cancer Center | Cd22 antibodies and methods of using the same |
| CA3136251A1 (en) * | 2019-04-08 | 2020-10-15 | Memorial Sloan Kettering Cancer Center | Cd19 antibodies and methods of using the same |
| CN115667925A (zh) * | 2020-05-15 | 2023-01-31 | 阿雷克森制药公司 | 使用细胞外囊泡来检测补体激活的方法以及其用于评估和/或监测补体介导的疾病的治疗的用途 |
| CN114558122B (zh) * | 2022-04-27 | 2023-02-21 | 北京肿瘤医院(北京大学肿瘤医院) | 放射核素标记的过氧化氢酶及其应用 |
| CA3262904A1 (en) * | 2022-09-21 | 2024-03-28 | Elthera Ag | NEW BINDING MOLECULES THAT BIND TO L1CAM |
| WO2024100200A1 (en) | 2022-11-09 | 2024-05-16 | Cis Pharma Ag | Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications |
| WO2025238187A1 (en) | 2024-05-15 | 2025-11-20 | Cis Biopharma Ag | Immunoconjugates targeting l1-cam |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107045A (en) * | 1994-06-30 | 2000-08-22 | Oklahoma Medical Research Foundation | Antibodies to lipoproteins and apolipoproteins and methods of use thereof |
| US6972323B1 (en) * | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| WO2007114550A1 (en) * | 2006-04-03 | 2007-10-11 | Korea Research Institute Of Bioscience And Biotechnology | A novel monoclonal antibody specific to the l1cam, a hybridoma producing the same and a method producing the same |
| MX2008015138A (es) | 2006-06-02 | 2009-01-28 | Aveo Pharmaceuticals Inc | Proteinas de union al factor de crecimiento de hepatocitos (fch). |
| AU2007288620B2 (en) * | 2006-08-23 | 2012-08-30 | Korea Research Instititute Of Bioscience And Biotechnology | A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangiocarcinoma |
| AU2008201871A1 (en) * | 2008-04-16 | 2009-11-26 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Inhibition of angiogenesis and tumor metastasis |
| KR101501736B1 (ko) | 2008-12-05 | 2015-03-12 | 한국생명공학연구원 | 인간 및 마우스에서 발현하는 ｌ1ｃａｍ에 특이적으로 결합하는 재조합 단일클론항체 및 그 이용 |
| CA2928846A1 (en) * | 2009-11-24 | 2011-06-03 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
| MX2013005847A (es) * | 2010-11-24 | 2013-12-12 | Glaxo Group Ltd | Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf. |
| LT2691417T (lt) * | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| CA2858806A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
| KR101504039B1 (ko) * | 2012-11-16 | 2015-03-19 | 강원대학교산학협력단 | 인간 및 마우스 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도 |
| CA2926215A1 (en) * | 2013-10-06 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified pseudomonas exotoxin a |
| CA3067351A1 (en) * | 2017-06-15 | 2018-12-20 | Nai-Kong Cheung | Anti-l1-cam antibodies and uses thereof |
-
2018
- 2018-06-14 CA CA3067351A patent/CA3067351A1/en active Pending
- 2018-06-14 CN CN201880052266.7A patent/CN111093693B/zh active Active
- 2018-06-14 EP EP18818419.6A patent/EP3638299A4/en active Pending
- 2018-06-14 CN CN202411020658.9A patent/CN119161477A/zh active Pending
- 2018-06-14 WO PCT/US2018/037645 patent/WO2018232188A1/en not_active Ceased
- 2018-06-14 US US16/622,274 patent/US11597764B2/en active Active
- 2018-06-14 JP JP2019569397A patent/JP7353187B2/ja active Active
-
2019
- 2019-12-12 IL IL271398A patent/IL271398A/en unknown
-
2023
- 2023-03-06 US US18/179,159 patent/US12486323B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wei et al. | Current landscape and future directions of bispecific antibodies in cancer immunotherapy | |
| Goebeler et al. | Bispecific and multispecific antibodies in oncology: opportunities and challenges | |
| Paul et al. | Cancer therapy with antibodies | |
| Barzaman et al. | Breast cancer immunotherapy: Current and novel approaches | |
| JP2022546572A5 (enExample) | ||
| IL273484B1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| JP2021531764A5 (enExample) | ||
| JP2023523584A5 (enExample) | ||
| JP2020534017A5 (enExample) | ||
| JP2020103301A5 (enExample) | ||
| Chandramohan et al. | Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy | |
| JP2023537002A5 (enExample) | ||
| Lutterbuese et al. | Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA | |
| JP2020534250A5 (enExample) | ||
| JP2022538117A5 (enExample) | ||
| FI3802608T3 (fi) | Cd3-vasta-aineita ja niiden käyttötapoja | |
| JP2020501531A5 (enExample) | ||
| JP2021520208A5 (enExample) | ||
| JP2021517816A5 (enExample) | ||
| JP2020507571A5 (enExample) | ||
| RU2017145150A (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| JP2022511471A5 (enExample) | ||
| Lan et al. | Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview | |
| JP2020512281A5 (enExample) | ||
| JP2015529641A5 (enExample) |